Medicare Enrolled
Dr. Alan Kramer, MD
Medical Oncology · San Francisco, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kramer from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kramer?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kramer
Dr. Alan Kramer is a medical oncology specialist in San Francisco, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Kramer performed 12,081 Medicare services across 919 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kramer received a total of $9,581 from 49 pharmaceutical and/or device companies across 414 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kramer is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 19% volume in CA
$9,581 industry payments
Medicare Practice Summary
Medicare Utilization ↗12,081
Medicare services
Top 19% in CA for medical oncology
919
Unique beneficiaries
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~636 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 3,780 | $17 | $59 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
3,340 | $6 | $22 |
| Anti-nausea injection (ondansetron/Zofran) | 1,200 | $0 | $10 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
816 | $8 | $24 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
746 | $6 | $6 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
718 | $78 | $218 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
666 | $0 | $9 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
196 | $14 | $35 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
150 | $113 | $306 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
139 | $140 | $355 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
108 | $30 | $76 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
89 | $1 | $11 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
70 | $20 | $51 |
| New patient office visit, complex (60-74 min) | 35 | $198 | $518 |
| Quadrivalent influenza vaccine, cell culture-derived A flu shot that protects against four strains of the influenza virus. It is produced using cell culture technology rather than traditional egg-based methods. |
14 | $32 | $65 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
14 | $37 | $50 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.4% high complexity
76.0% medium
20.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$9,581
Total received (2018-2024)
Avg $1,369/year across 7 years
Top 37% in CA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
49
Companies
414
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,224 (96.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$356 (3.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,537
2023
$1,559
2022
$582
2021
$726
2020
$1,416
2019
$1,556
2018
$1,204
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$300
PFIZER INC.
$278
ABBVIE INC.
$245
Novartis Pharmaceuticals Corporation
$218
Stemline Therapeutics Inc.
$192
Coherus Biosciences Inc.
$138
Janssen Biotech, Inc.
$131
E.R. Squibb & Sons, L.L.C.
$110
Lilly USA, LLC
$109
Merck Sharp & Dohme LLC
$94
ARRAY BIOPHARMA INC
$93
Daiichi Sankyo Inc.
$86
Takeda Pharmaceuticals U.S.A., Inc.
$85
Regeneron Healthcare Solutions, Inc.
$79
Ipsen Biopharmaceuticals, Inc
$65
GENZYME CORPORATION
$63
Genentech USA, Inc.
$60
Incyte Corporation
$58
EMD Serono, Inc.
$56
Immunocore Limited
$35
Kite Pharma, Inc.
$24
Rigel Pharmaceuticals, Inc.
$18
Top 3 companies account for 32.5% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$1,161
AstraZeneca Pharmaceuticals LP
$1,142
PFIZER INC.
$659
Novartis Pharmaceuticals Corporation
$639
Janssen Biotech, Inc.
$399
Merck Sharp & Dohme Corporation
$348
Pharmacyclics LLC, An AbbVie Company
$306
Regeneron Healthcare Solutions, Inc.
$253
Takeda Pharmaceuticals U.S.A., Inc.
$249
ABBVIE INC.
$245
Seagen Inc.
$233
Lilly USA, LLC
$224
ARRAY BIOPHARMA INC
$219
Daiichi Sankyo Inc.
$215
Merck Sharp & Dohme LLC
$209
Intuitive Surgical, Inc.
$196
Stemline Therapeutics Inc.
$192
Incyte Corporation
$191
Eisai Inc.
$183
Exelixis Inc.
$182
Genentech USA, Inc.
$178
Coherus Biosciences Inc.
$177
Taiho Oncology, Inc.
$174
Celgene Corporation
$166
Amgen Inc.
$148
Seattle Genetics, Inc.
$116
Foundation Medicine, Inc.
$113
EISAI INC.
$94
GENZYME CORPORATION
$92
Rigel Pharmaceuticals, Inc.
$90
Ipsen Biopharmaceuticals, Inc
$77
GlaxoSmithKline, LLC.
$65
Mirati Therapeutics, Inc.
$64
Bayer HealthCare Pharmaceuticals Inc.
$62
Astellas Pharma US Inc
$56
EMD Serono, Inc.
$56
Genentech, Inc.
$53
Helsinn Therapeutics (U.S.), Inc.
$40
Mylan Institutional Inc.
$35
Immunocore Limited
$35
NOVARTIS PHARMACEUTICALS CORPORATION
$34
Heron Therapeutics, Inc.
$33
Deciphera Pharmaceuticals Inc.
$29
Blueprint Medicines Corporation
$28
Gilead Sciences, Inc.
$25
Puma Biotechnology, Inc.
$25
Alexion Pharmaceuticals, Inc.
$24
Kite Pharma, Inc.
$24
Jazz Pharmaceuticals Inc.
$19
Top 3 companies account for 30.9% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ALUNBRIG · Alecensa · BALVERSA · BAVENCIO · BOSULIF · BRAFTOVI · Balversa · CALQUENCE · CYRAMZA · Cabometyx · DARZALEX · Da Vinci Surgical System · ELREXFIO · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · Enhertu · Erleada · FASLODEX · FOUNDATIONONE · FRUZAQLA · FULPHILA · GAVRETO · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · IRESSA · Imbruvica · JAKAFI · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LOQTORZI · LORBRENA · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · NERLYNX · NINLARO · OPDIVO · OPDUALAG · Onivyde · Orserdu · PADCEV · PIQRAY · Perjeta · Pomalyst · Prolia · QINLOCK · REBLOZYL · RYBREVANT · Revlimid · Rezlidhia · SARCLISA · SOMATULINE DEPOT · SPRYCEL · SUSTOL · Stivarga · TAFINLAR · TAGRISSO · TECENTRIQ · TUKYSA · Tavalisse · Tecentriq · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VOTRIENT · Vectibix · Venclexta · Vitrakvi · XALKORI · XOSPATA · XTANDI · Yescarta · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
30
Per 100K population
3.6
County median income
$141,446
Nearest hospital
KAISER FOUNDATION HOSPITAL - SAN FRANCISCO
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kramer is a mixed practice specialist, with above-average Medicare volume (top 19% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kramer experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Kramer performed 3,780 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kramer receive payments from pharmaceutical companies?
Yes. Dr. Kramer received a total of $9,581 from 49 companies across 414 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kramer's costs compare to other medical oncologists in San Francisco?
Dr. Kramer's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kramer) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in San Francisco
Browse medical oncologists in San Francisco ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in CA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in CA
Which CA medical oncologists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology